article
Issue #6 2016 – Digital version
Read the free-to-view digital version of the latest issue of European Pharmaceutical Review...
List view / Grid view
Oncology
news
ESMO 2016: New data from Eisai’s oncology portfolio for halaven (eribulin), lenvima (lenvatinib) and kisplyx (lenvatinib)
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review will of course keep you up to date with all the latest pharma news from the conference. Here's a preview snippet...
news
Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
news
Initiation of HTL1071 trial triggers $10m payment to Heptares
6 July 2016 | By Victoria White, Digital Content Producer
The first subject has been dosed with immuno-oncology candidate HTL1071 in a Phase I clinical study, triggering a US$10 million payment to Heptares...
news
Positive results for Yeliva in Phase I advanced solid tumour study
4 July 2016 | By Victoria White, Digital Content Producer
Yeliva is a first-in-class, orally-administered sphingosine kinase-2 (SK2) selective inhibitor with anticancer and anti-inflammatory activities...
news
Xilonix demonstrates significant clinical response in colorectal cancer study
4 July 2016 | By Victoria White, Digital Content Producer
XBiotech’s Xilonix is the first monoclonal antibody immunotherapy to specifically target and neutralise interleukin-1 alpha (IL-1α)...
news
BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer
1 July 2016 | By Victoria White, Digital Content Producer
The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients...
news
Global urological cancers market to double by 2022, says GBI Research
30 June 2016 | By Victoria White, Digital Content Producer
The urological cancers market will increase from $17.9 billion in 2015 to $35.9 billion by 2022, according to business intelligence provider GBI Research...
news
Regorafenib increases overall survival in hepatocellular carcinoma study
29 June 2016 | By Victoria White, Digital Content Producer
Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced...
news
Novartis and Xencor enter bispecific antibody collaboration
28 June 2016 | By Victoria White, Digital Content Producer
The collaboration includes XmAb Bispecific Technology for 4 Novartis targets and access to Xencor Fc Technologies...
news
Cancer immunotherapy drugs linked to autoimmune diseases
24 June 2016 | By Victoria White, Digital Content Producer
Some cancer patients taking the immunotherapy drugs ipilimumab and nivolumab may be at a higher-than-normal risk of developing autoimmune diseases...
news
Phase I/II trial of INCAGN1876 in solid tumours starts
22 June 2016 | By Victoria White, Digital Content Producer
The open-label, dose-escalation portion of the trial will evaluate the safety and tolerability of INCAGN1876 in patients with solid tumours...
news
Denosumab may prevent breast cancer in women with BRCA1 gene mutation
20 June 2016 | By Victoria White, Digital Content Producer
Researchers have discovered that an existing medication, denosumab, may prevent breast cancer in women carrying a faulty BRCA1 gene...
news
Chemo may boost immunotherapy power in ovarian cancer
15 June 2016 | By Victoria White, Digital Content Producer
A study has found that women with ovarian cancer may benefit more from immunotherapy drug treatments if they are given straight after chemotherapy...
news
Tecentriq to dominate the bladder cancer market, says GlobalData
14 June 2016 | By Victoria White, Digital Content Producer
The launch of Roche’s Tecentriq will usher in a dramatic change in the treatment paradigm of bladder cancer, according to an analyst with GlobalData...